Article Text

Download PDFPDF
Surgical Scar Site Recurrence in Patients With Cervical Cancer on 18F-FDG PET-CT: A Case-Control Study
  1. Sunesh Kumar,
  2. Varun S. Dhull, MD*,
  3. Bangkim C. Khangembam, MD*,
  4. Punit Sharma, MD*,
  5. Neelima Rana, MD,
  6. Satyavrat Verma, MBBS*,
  7. Dayanand Sharma, MD,
  8. Shamim A. Shamim, MD* and
  9. Rakesh Kumar, PhD*
  1. *Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India;
  2. Department of Radiodiagnosis, M S Ramaiah Medical College, Bengaluru, India; and
  3. Department of Radiation Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  1. Address correspondence and reprint requests to Rakesh Kumar, MD, PhD, E-81, Ansari Nagar (East), AIIMS Campus, New Delhi-110029, India. E-mail:


Purpose The purpose of this study was to assess the role of fluorine 18 (18F)-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) in evaluating various parameters in patients with surgical scar site recurrence in cervical carcinoma.

Methods Data of all patients with cervical cancer (n = 329) who underwent PET-CT at our institute between 2005 and 2013 was reviewed. Of these 329 patients, 132 patients who were surgically treated and underwent restaging/follow-up PET-CT were included in the present study for final analysis. Tumor recurrence at the abdominal surgical scar site was looked for. Abnormal uptakes suggestive of active disease at other sites were also noted. Maximum standardized uptake value was measured for all the lesions. Patients with scar site recurrence were taken as cases (n = 6), whereas the remaining patients served as controls (n = 126). Comparison with conventional imaging modalities was made wherever available. Histopathological examination was always sought for.

Results The incidence of scar site recurrence after surgery was found to be 4.5% (6/117). A total of 56 of 132 patients had recurrent disease, including 6 patients with scar site recurrence. All of the patients with scar site recurrence also had recurrent disease at other sites (local, nodal, or distant). Conventional imaging modalities were available in 4 of these 6 patients and detected scar site recurrence in 3 of those 4 patients. In patients with scar site recurrence, the mean ± SD time to scar site recurrence was 14.0 ± 10.9 months (median, 10 months; range, 7–36 months). Significant difference was seen between cases and control for International Federation of Genecology and Oncology stage (P = 0.001) and nodal recurrence (P = 0.007). Additionally, age, nodal recurrence, distant recurrence, and scar site recurrence were significantly associated with death.

Conclusions Scar site recurrence carries a poor prognosis, and the incidence is much higher than previously known when PET-CT is used as a modality for its detection.

  • Cervical carcinoma
  • Surgical scar site
  • Recurrence
  • 18F-FDG PET-CT

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • No funding was received from any organization for the study.

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (